Systemic delivery, targeted action

Cancer Targeting Systems (CTS) is developing a new non-viral, gene therapy-based approach for the treatment of cancer. Nanoparticles are administered systemically, distribute throughout the patient’s body and address metastatic tumours. Gene expression of a therapeutic payload is cancer cell specific, and triggers local activation of the immune system, leading to cancer cell destruction.

Products

CTS’s products are nanoparticles, microscopic spheres of plasmid DNA formulated inside an FDA approved polymer coat. Unlike predominant virus-delivered gene therapies, CTS’s nanoparticles can be delivered systemically by intravenous injection, with repeated dosing. They are well distributed throughout the body, and so are able to target cancer cells that have spread.

The nanoparticles are manufactured by a proprietary method to produce safe and reproducible formulations; they can be freeze-dried for long-term storage without losing efficacy and rapidly reconstituted for easy administration.

The therapeutic payload genes delivered by CTS’s nanoparticles are under the tight control of a proprietary cancer-specific switch, which is active in cancer cells but not normal cells. In the first instance, the company is focussing on the delivery of IL-12, a key immune activator that mobilises the body’s defences to destroy cancer cells. IL-12 has been of significant clinical interest for many years, but is challenging to deliver systemically without causing unacceptable side effects. CTS, by ensuring that IL-12 is expressed only within tumour cells, and at a low, but therapeutically relevant level, overcomes this issue.

CTS’s first product is at the pre-clinical stage of development with in vivo proof of principle achieved. It is planned to be in the clinic in 2019 for metastatic lung cancer.

Platform

CTS draws on world leading research, principally at Johns Hopkins University, with a series of collaborations and exclusively licenced patents.

CTS’s products combine a proprietary method for making precisely controlled nanoparticle preparations that can deliver gene-based therapies, with a patented system that ensures that therapeutic gene payload expression only occurs within the cancer cells. The nanoparticles are easy to administer intravenously and can disseminate throughout the patient’s body, thus addressing dispersed tumours.

The first therapeutic gene payload being developed for the clinic by the company is IL-12, a cytokine that is a key immune signalling protein. This will be used as an initial clinical proof of principle. There is an array of other potentially therapeutic gene payloads that could be delivered with CTS’s platform for different modes of action in treating cancer, including other immune-modulatory agents, peptides and antibody fragments.

Board

Martin Pomper

Director

Co-scientific founder of CTS, practicing clinician and Professor of Radiology at Johns Hopkins University.

View profile

Will West

President & CEO

20 years’ experience of product discovery and development in biotech and pharma. BIA Board, BBSRC Council.

View profile

Jason R. Dinges

Director

Investor Director representing CTS’ main shareholder. Molecular biology background and qualified patent attorney.

View profile

News

CTS Inc. up and running

CTS is a new business focused on delivering cancer theranostic products - combining imaging with therapy. The lead platform is a gene-based technology based on cancer cell-specific gene promoters, licenced from Johns Hopkins University, VCU and Columbia University.

Read article View more news

Contact

Email: info@cts-bioscience.com
Telephone: +44 1799 531 130

Email us

UK operating address:
The Mansion,
Chesterford Research Park
Cambridge
CB10 1XL
UK

US registered address:
Cancer Targeting Systems, Inc.
1188 Centre Street
Newton Centre
Boston, MA 02459
USA

Systemic delivery, targeted action

Cancer Targeting Systems (CTS) is developing a new non-viral, gene therapy-based approach for the treatment of cancer. Nanoparticles are administered systemically, distribute throughout the patient’s body and address metastatic tumours. Gene expression of a therapeutic payload is cancer cell specific, and triggers local activation of the immune system, leading to cancer cell destruction.

Products

CTS’s products are nanoparticles, microscopic spheres of plasmid DNA formulated inside an FDA approved polymer coat. Unlike predominant virus-delivered gene therapies, CTS’s nanoparticles can be delivered systemically by intravenous injection, with repeated dosing. They are well distributed throughout the body, and so are able to target cancer cells that have spread.

The nanoparticles are manufactured by a proprietary method to produce safe and reproducible formulations; they can be freeze-dried for long-term storage without losing efficacy and rapidly reconstituted for easy administration.

The therapeutic payload genes delivered by CTS’s nanoparticles are under the tight control of a proprietary cancer-specific switch, which is active in cancer cells but not normal cells. In the first instance, the company is focussing on the delivery of IL-12, a key immune activator that mobilises the body’s defences to destroy cancer cells. IL-12 has been of significant clinical interest for many years, but is challenging to deliver systemically without causing unacceptable side effects. CTS, by ensuring that IL-12 is expressed only within tumour cells, and at a low, but therapeutically relevant level, overcomes this issue.

CTS’s first product is at the pre-clinical stage of development with in vivo proof of principle achieved. It is planned to be in the clinic in 2019 for metastatic lung cancer.

Platform

CTS draws on world leading research, principally at Johns Hopkins University, with a series of collaborations and exclusively licenced patents.

CTS’s products combine a proprietary method for making precisely controlled nanoparticle preparations that can deliver gene-based therapies, with a patented system that ensures that therapeutic gene payload expression only occurs within the cancer cells. The nanoparticles are easy to administer intravenously and can disseminate throughout the patient’s body, thus addressing dispersed tumours.

The first therapeutic gene payload being developed for the clinic by the company is IL-12, a cytokine that is a key immune signalling protein. This will be used as an initial clinical proof of principle. There is an array of other potentially therapeutic gene payloads that could be delivered with CTS’s platform for different modes of action in treating cancer, including other immune-modulatory agents, peptides and antibody fragments.

Board

Martin Pomper

Director

Co-scientific founder of CTS, practicing clinician and Professor of Radiology at Johns Hopkins University.

View profile

Will West

President & CEO

20 years’ experience of product discovery and development in biotech and pharma. BIA Board, BBSRC Council.

View profile

Jason R. Dinges

Director

Investor Director representing CTS’ main shareholder. Molecular biology background and qualified patent attorney.

View profile

News

CTS Inc. up and running

CTS is a new business focused on delivering cancer theranostic products - combining imaging with therapy. The lead platform is a gene-based technology based on cancer cell-specific gene promoters, licenced from Johns Hopkins University, VCU and Columbia University.

Read article View more news

Contact

Email: info@cts-bioscience.com
Telephone: +44 1799 531 130

Email us

UK operating address:
The Mansion,
Chesterford Research Park
Cambridge
CB10 1XL
UK

US registered address:
Cancer Targeting Systems, Inc.
1188 Centre Street
Newton Centre
Boston, MA 02459
USA